Xylocaine Viscous

Land: Nýja-Sjáland

Tungumál: enska

Heimild: Medsafe (Medicines Safety Authority)

Virkt innihaldsefni:

Lidocaine hydrochloride monohydrate 21.3 mg/mL equivalent to 20 mg Lignocaine hydrochloride anhydrous

Fáanlegur frá:

Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics

INN (Alþjóðlegt nafn):

Lidocaine hydrochloride monohydrate 21.3 mg/mL (=20 mg Lignocaine hydrochloride anhydrous)

Skammtar:

2% w/v

Lyfjaform:

Oral solution

Samsetning:

Active: Lidocaine hydrochloride monohydrate 21.3 mg/mL equivalent to 20 mg Lignocaine hydrochloride anhydrous Excipient: Carmellose sodium Cherry Extract Fache 5913G Methyl hydroxybenzoate Propyl hydroxybenzoate Purified water Saccharin sodium Sodium hydroxide

Einingar í pakka:

Bottle, plastic, Tampertel cap, 1x200mL, 200 mL

Tegund:

Pharmacy only

Gerð lyfseðils:

Pharmacy only

Framleitt af:

Cambrex Karlskoga AB

Ábendingar:

Xylocaine Viscous solution is indicated for the relief of pain and discomfort associated with: · irritated or inflamed mucous membranes of the mouth, pharynx and upper gastrointestinal tract, e.g. post-tonsillectomy sore throat, dumping syndrome · introduction of instruments and catheters into the respiratory and gastrointestinal tract.

Vörulýsing:

Package - Contents - Shelf Life: Bottle, plastic, Tampertel cap, child resistant - 200 mL - 36 months from date of manufacture stored at or below 25°C

Leyfisdagur:

1994-12-06

Vara einkenni

X
YLOCAINE
V
ISCOUS
Data Sheet
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
Xylocaine
®
Viscous solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each
mL
of
Xylocaine
Viscous
contains
lignocaine
hydrochloride
monohydrate 21.4 mg (equivalent to lignocaine hydrochloride 20 mg).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Xylocaine Viscous solution is a clear to almost clear slightly
coloured viscous
liquid.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Xylocaine Viscous solution is indicated for the relief of pain and
discomfort
associated with:
•
irritated or inflamed mucous membranes of the mouth, pharynx and
upper
gastrointestinal
tract,
e.g.
post-tonsillectomy
sore
throat,
dumping syndrome;
•
introduction
of
instruments
and
catheters
into
the
respiratory
and
gastrointestinal tract.
4.2
DOSE AND METHOD OF ADMINISTRATION
As with any local anaesthetic, reactions and complications are best
averted
by employing the minimal effective dosage. Debilitated, acutely ill or
elderly
patients and children should be given doses commensurate with their
age
and physical condition.
Shake the bottle well before use.
For symptomatic treatment of irritated or inflamed mucous membranes of
the
mouth and pharynx, the usual adult dose is 15 mL undiluted. For use in
the
mouth, the solution should be swished around the mouth for
approximately 30
seconds and spat out. For use on the pharynx, the solution should be
gargled and may be swallowed. This dose should not be administered at
intervals of less than three hours.
MAXIMUM DOSAGE
Although the incidence of adverse effects with lignocaine is quite
low, caution
should be exercised when using large amounts.
X
YLOCAINE
V
ISCOUS
Data Sheet
Copyright
2
ADULTS: No more than 15 mL (300 mg lignocaine HCl) every 3 hours or
120 mL in a 24 hour period.
CHILDREN OVER 3 YEARS OF AGE: No more than 4 mg/kg (0.2 mL/kg) of
bodyweight or 5 mL (100 mg lignocaine HCl), whichever is lower. No
more
than 4 doses should be given in a 24 hour period. The dose should not
be
a